Previous Article | Next Article 
Infection and Immunity, December 2006, p. 7010-7013, Vol. 74, No. 12
0019-9567/06/$08.00+0 doi:10.1128/IAI.00071-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Proinflammatory and Antimicrobial Nitric Oxide in Gingival Fluid of Diabetic Patients with Periodontal Disease
Uros Skaleric,1*
Boris Gaspirc,1
Nancy McCartney-Francis,2
Andrej Masera,3 and
Sharon M. Wahl2
Department of Oral Medicine & Periodontology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia,1
Oral Infection & Immunity Branch, NIDCR, NIH, Bethesda, Maryland,2
Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia3
Received 13 January 2006/
Returned for modification 27 February 2006/
Accepted 23 September 2006

ABSTRACT
Abnormal nitric oxide (NO) synthesis has been implicated in
the pathogenesis of both periodontal disease and diabetes mellitus.
In diabetic patients, increased inducible NO synthase in inflamed
gingiva correlated with NO in gingival crevicular fluid. Although
increased NO reflected more-severe inflammation, it was associated
with reductions in CFU of
Prevotella intermedia, a major periodontopathogen,
highlighting dual roles for NO.

TEXT
Nitric oxide (NO), a toxic free radical (
25) with multiple biological
functions, including inhibition of neutrophil chemotaxis (
14),
adhesion to endothelium (
17), and upregulation of tumor necrosis
factor alpha (
29), is generated by oxidative deamination of
L-arginine by nitric oxide synthase (NOS). The inducible form
of NOS (iNOS) is rapidly and durably expressed by inflammatory
cells in response to bacteria or their products, such as lipopolysaccharide
(LPS) (
32). Small amounts of NO induced by constitutive NOS
are considered beneficial, whereas excess iNOS-induced NO can
mediate cell and tissue injury. Periodontal diseases are chronic
inflammatory infections associated with gram-negative bacteria,
including
Porphyromonas gingivalis,
Prevotella intermedia, and
Actinobacillus actinomycetemcomitans (
26), which stimulate macrophages
to generate NO (
1,
7,
16). Moreover, NO is increased in inflamed
gingival tissue (
11,
15), and mercaptoethylguanidine, a selective
iNOS inhibitor, prevents bone destruction in ligature-induced
rodent periodontitis (
21).
Periodontal disease is often a chronic complication of diabetes mellitus (20), with evidence of increased gingival inflammation, deeper periodontal pockets, and greater clinical attachment and bone loss (22). Hyperglycemia stimulates the production of advanced glycolysated end products, enhances the polyol pathway, and activates protein kinase C, which may lead to increased oxidative stress (12). Increased NO concentrations were demonstrated in sera of patients with type I diabetes and persistent microalbuminuria (2).
The aim of our study was to evaluate expression of NO in gingivae of type I diabetic patients presenting with periodontal disease and to correlate the level of NO with P. intermedia infection. Gingival tissues were obtained during modified Widman flap surgery from diabetic patients (three males and two females; mean age [±standard deviation], 48.2 ± 6.9 years) diagnosed with moderate (probing depth of
5 mm) or advanced (probing depth of >5 mm) periodontitis. Noninflamed gingival tissue was obtained during the crown-lengthening procedure of diabetic patients (two females, aged 44 and 51 years) (protocol approved by National Medical Ethics Committee of Slovenia; patients signed informed consent). Fixed and embedded tissue sections were stained with hematoxylin-eosin (H&E) or antibodies against iNOS (monoclonal antibody 9502, 1:100 in 1% bovine serum albumin; R&D Systems, Minneapolis, MN), CD29 (monoclonal antibody 1778, 1:100; R&D Systems, Minneapolis, MN), and CD68 (M0876, 1:50; DAKO Corporation, Carpinteria, CA) by use of an indirect biotin streptavidin system for detection (basic 3,3'-diaminobenzidine tetrahydrochloride detection kit 760-001; Ventana Medical Systems, Tucson, AZ) (18). An intense inflammatory infiltrate composed predominantly of mononuclear cells, including lymphocytes and macrophages, was observed in H&E-stained gingival tissues from periodontally involved type 1 diabetic patients (Fig. 1a). Immunostaining confirmed the presence of CD68-positive macrophages (Fig. 1c) within the inflammatory site as well as CD29-positive fibroblasts (Fig. 1b) along the margins of the infiltrate. Importantly, iNOS-positive cells were identified within the lesion (Fig. 1d). Similarly to the results of Hirose et al. (11), who did not find iNOS expression in noninflamed gingival tissue of nondiabetic patients, we did not demonstrate iNOS expression in noninflamed gingival tissue of our diabetic patients (data not shown).
Based on the elevated iNOS expression in inflamed gingival tissue,
gingival fluid samples were obtained from diabetic patients
(13 males and 5 females; mean age, 38.8 years; range, 24 to
58 years; mean duration of diabetes, 16.1 years; range, 5 to
35 years) by use of 2-µl microcapillary tubes (Drummond
Co., Pennsylvania). Fluid was diluted into 50 µl phosphate-buffered
saline containing gentamicin (10 µg/ml), filtered (Ultrafree
microcentrifuge filter, 10,000 molecular weight), treated with
nitrate reductase to convert nitrate to nitrite, and reacted
with 2,3-diaminonaphthalene (
23). Fluorescence was measured
at a wavelength of 365/450 (excitation/emission) by use of a
fluorescence plate reader (Idexx Laboratories, Westbrook, ME)
and based on a standard curve, with data reported as µM
nitrite plus nitrate. Patients were assessed for degree of periodontitis
by plaque index (PI), gingival index (GI) (
19), probing depth,
and clinical attachment loss (mm) by electronic periodontal
probe (Peri-probe; Vivadent, Liechtenstein) and Williams periodontal
probe. Consistent with iNOS detection in tissues, NO was quantified
in all fluid samples, ranging from 10.7 to 86.0 µM (mean,
22.98 ± 4.32 µM). Samples from tooth sites with
small or moderate plaque (PI of 1 or 2) contained increased
NO, although the difference was not significant compared to
sites with no plaque (PI of 0) (
P > 0.05, Student's
t test).
Based on gingival inflammation, sites with a GI of 1 or 2 contained
significantly higher NO than those with no inflammation (GI
of 0) (
P = 0.012). Likewise, significantly increased NO in gingival
exudates was associated with sites of increased probing depth
(
r2 = 0.34,
P < 0.05, correlation and polynomial regression
analysis) (Fig.
2), all consistent with higher NO in the inflamed
sites.
Because
Prevotella intermedia is one of the causative pathogens
of periodontal disease and
P. intermedia LPS induces iNOS and
release of NO in murine macrophages (
12), we analyzed DNA from
subgingival plaque samples (isolated from the same sites where
the gingival crevicular fluid was collected) of 18 diabetic
patients for
P. intermedia. Loosely adherent supragingival plaque
in the intercanine sector was gently removed by cotton gauze.
A sterile paper point was inserted into the apical extent of
periodontal pocket sulcus for 10 s, and after elution and denaturation,
samples were analyzed by slot blot analysis for bacterial species,
including
P. intermedia (Omnigene Laboratory, Cambridge, MA),
as described by French et al. (
6). Questions regarding the sensitivity
and specificity of the Omnigene probe for
P. intermedia have
been raised by van Steenbergen et al. (
30), who claimed that
the Omnigene probe did not distinguish between
P. intermedia and
Prevotella nigrescens. Quantitative differentiation between
P. intermedia and
P. nigrescens by oligonucleotide probes to
specific rRNA sequences, as described by Gmür and Thurnheer
(
8), was not performed in our study. However, Moore et al. (
24)
detected five times as many
P. intermedia CFU as
P. nigrescens CFU in periodontal pockets but found seven times more
P. nigrescens CFU than
P. intermedia CFU at healthy sites. In addition, Dahlen
et al. (
4) identified two-thirds of their
P. intermedia-like
isolates from "destructive periodontal disease" as
P. intermedia isolates, whereas 75% of the isolates from healthy control subjects
were
P. nigrescens isolates. According to these results and
the fact that our subgingival plaque samples were collected
predominantly from moderate and deep periodontal pockets, we
assume that
P. intermedia and not
P. nigrescens was the main
detected species in our samples.
P. intermedia isolates were
detected in our plaque samples, ranging from 0 to 310
x 10
3 bacteria. When
P. intermedia levels were compared by polynomial
regression analysis, based on the depth of the periodontal pocket
source, we found a modest increase in
P. intermedia DNA in moderate
depth pockets (<6 mm) but decreased numbers in pockets deeper
than 8 mm (Fig.
2). Importantly, polynomial regression analysis
of NO and
P. intermedia in periodontal pockets confirmed the
reduction in
P. intermedia DNA in pockets where NO levels were
increased (Fig.
3) (
r2 = 0.34,
P < 0.05).
The correlation between increased NO in gingival fluid and decreased
CFU of the periodontal pathogen
P. intermedia in deep periodontal
pockets (>6 mm) suggested a possible microbicidal effect.
Nitric oxide induced by iNOS has been shown to possess immunomodulatory,
cytotoxic, and antibacterial effects (
33), consistent with a
role for reactive oxygen and nitrogen species in periodontal
tissue damage as well as in microbial killing. Recent data indicate
that modulation of superoxide levels by NO influences phagocytic
functions of neutrophils and macrophages and that NO is an important
element of host defense against
P. gingivalis (
9). Since
P. gingivalis LPS can also induce macrophages to produce NO in
an
L-arginine- and gamma interferon-dependent mechanism (
27),
this NO may potentially be an important mediator of bone resorption.
In this regard, iNOS null mice demonstrate a significantly reduced
osteoclast response (
13). In addition, iNOS influences both
osteoblast and osteocyte function in bone remodeling (
31).
The assessment of NO stable end products, nitrite and nitrate (NOx), is commonly used as a measure of NO production in biological fluids. Both NOx and vascular endothelial growth factor concentrations are increased, although not related, in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy (10), and NO has been implicated in angiogenesis (3). Rapid serum diffusion of NO could contribute to increased aqueous NOx (10), implicating NO in the pathophysiology and progression of diabetic retinopathy (28) as well as in periodontal disease. These molecules may serve as therapeutic targets for the treatment and/or prevention of systemic and ocular microvascular complications in diabetes (5). Similarly, subgingival local delivery of NO inhibitors might be useful in the treatment of periodontal inflammation, particularly as systemic delivery of an NO inhibitor was shown to reduce bone resorption in an animal model of experimental periodontitis (21).

ACKNOWLEDGMENTS
This study was supported by the Ministry of Education and Science
of Republic Slovenia (periodontal medicine research grant no.
K71/P3-0293) and in part by the Intramural Research Program
of the NIH, National Institute of Dental and Craniofacial Research.

FOOTNOTES
* Corresponding author. Mailing address: Department of Oral Medicine & Periodontology, Faculty of Medicine, Hrvatski trg 6, 1000 Ljubljana, Slovenia. Phone: 386 1 3002110. Fax: 386 1 5222494. E-mail:
uros.skaleric{at}mf.uni-lj.si.

Published ahead of print on 2 October 2006. 
Editor: F. C. Fang

REFERENCES
1 - Blix, I. J., and K. Helgeland. 1998. LPS from Actinobacillus actinomycetemcomitans and production of nitric oxide in murine macrophages J774. Eur. J. Oral Sci. 106:576-581.[CrossRef][Medline]
2 - Chiarelli, F., F. Cipollone, F. Romano, S. Tumini, F. Costantini, L. di Ricco, M. Pomilio, S. D. Pierdomenico, M. Marini, F. Cuccurullo, and A. Mezzetti. 2000. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 49:1258-1263.[Abstract]
3 - Cooke, J. P. 2003. NO and angiogenesis. Atheroscler. Suppl. 4:53-60.[Medline]
4 - Dahlén, G., M. Wikström, S. Renvert, R. Gmür, and B. Guggenheim. 1990. Biochemical and serological characterization of Bacteroides intermedius strains isolated from the deep periodontal pocket. J. Clin. Microbiol. 28:2269-2274.[Abstract/Free Full Text]
5 - Doganay, S., C. Evereklioglu, H. Er, Y. Turkoz, A. Sevinc, N. Mehmet, and H. Savli. 2002. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16:163-170.[CrossRef][Medline]
6 - French, C. K., E. D. Savitt, S. L. Simon, S. M. Eklund, M. C. Chen, L. C. Klotz, and K. K. Vaccaro. 1986. DNA probe detection of periodontal pathogens. Oral Microbiol. Immunol. 1:58-62.[Medline]
7 - Frolov, I., Y. Houri-Hadad, A. Soskolne, and L. Shapira. 1998. In vivo exposure to Porphyromonas gingivalis up-regulates nitric oxide but suppresses tumour necrosis factor-alpha production by cultured macrophages. Immunology 93:323-328.[CrossRef][Medline]
8 - Gmür, R., and T. Thurnheer. 2002. Direct quantitative differentiation between Prevotella intermedia and Prevotella nigrescens in clinical specimens. Microbiology 148:1379-1387.[Abstract/Free Full Text]
9 - Gyurko, R., G. Boustany, P. L. Huang, A. Kantarci, T. E. Van Dyke, C. A. Genco, and F. C. Gibson III. 2003. Mice lacking inducible nitric oxide synthase demonstrate impaired killing of Porphyromonas gingivalis. Infect. Immun. 71:4917-4924.[Abstract/Free Full Text]
10 - Hernandez, C., A. Lecube, R. M. Segura, L. Sararols, and R. Simo. 2002. Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabet. Med. 19:655-660.[CrossRef][Medline]
11 - Hirose, M., K. Ishihara, A. Saito, T. Nakagawa, S. Yamada, and K. Okuda. 2001. Expression of cytokines and inducible nitric oxide synthase in inflamed gingival tissue. J. Periodontol. 72:590-597.[CrossRef][Medline]
12 - Honing, M. L., P. J. Morrison, J. D. Banga, E. S. Stroes, and T. J. Rabelink. 1998. Nitric oxide availability in diabetes mellitus. Diabetes Metab. Rev. 14:241-249.[CrossRef][Medline]
13 - Jung, J. Y., A. C. Lin, L. M. Ramos, B. T. Faddis, and R. A. Chole. 2003. Nitric oxide synthase I mediates osteoclast activity in vitro and in vivo. J. Cell. Biochem. 89:613-621.[CrossRef][Medline]
14 - Kaplan, S. S., T. Billiar, R. D. Curran, U. E. Zdziarski, R. L. Simmons, and R. E. Basford. 1989. Inhibition of chemotaxis Ng-monomethyl-L-arginine: a role for cyclic GMP. Blood 74:1885-1887.[Abstract/Free Full Text]
15 - Kendall, H. K., H. R. Haase, H. Li, Y. Xiao, and P. M. Bartold. 2000. Nitric oxide synthase type-II is synthesized by human gingival tissue and cultured human gingival fibroblasts. J. Periodontal Res. 35:194-200.[CrossRef][Medline]
16 - Kim, S. J., M. S. Ha, E. Y. Choi, J. I. Choi, and I. S. Choi. 2004. Prevotella intermedia lipopolysaccharide stimulates release of nitric oxide by inducing expression of inducible nitric oxide synthase. J. Periodontal Res. 39:424-431.[CrossRef][Medline]
17 - Kubes, P., M. Suzuki, and D. N. Granger. 1991. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA 88:4651-4655.[Abstract/Free Full Text]
18 - Lloyd, R. V., K. Schmidt, L. Blaivas, J. P. McCoy, and B. S. Wilson. 1985. A rapid immunostaining method utilizing preformed antibody-avidin-biotin-peroxidase complexes. Am. J. Clin. Pathol. 83:636-639.[Medline]
19 - Loe, H. 1967. The gingival index, the plaque index and the retention index systems. J. Periodontol. 38(Suppl.):610-616.[Medline]
20 - Loe, H. 1993. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 16:329-334.[Medline]
21 - Lohinai, Z., P. Benedek, E. Feher, A. Gyorfi, L. Rosivall, A. Fazekas, A. L. Salzman, and C. Szabo. 1998. Protective effects of mercaptoethylguanidine, a selective inhibitor of inducible nitric oxide synthase, in ligature-induced periodontitis in the rat. Br. J. Pharmacol. 123:353-360.[CrossRef][Medline]
22 - Mealey, B. 1999. Diabetes and periodontal diseases. J. Periodontol. 70:935-949.[CrossRef][Medline]
23 - Misko, T. P., R. J. Schilling, D. Salvemini, W. M. Moore, and M. G. Currie. 1993. A fluorometric assay for the measurement of nitrite in biological samples. Anal. Biochem. 214:11-16.[CrossRef][Medline]
24 - Moore, L. V., W. E. Moore, E. P. Cato, R. M. Smibert, J. A. Burmeister, A. M. Best, and R. R. Ranney. 1987. Bacteriology of human gingivitis. J. Dent. Res. 66:989-995.[Abstract/Free Full Text]
25 - Palmer, R. M., A. G. Ferrige, and S. Moncada. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526.[CrossRef][Medline]
26 - Socransky, S. S., and A. D. Haffajee. 1992. The bacterial etiology of destructive periodontal disease: current concepts. J. Periodontol. 63:322-331.[Medline]
27 - Sosroseno, W. 2000. Nitric oxide production by murine spleen cells stimulated with Porphyromonas gingivalis-derived lipopolysaccharide. Asian Pac. J. Allergy Immunol. 18:209-214.[Medline]
28 - Tsai, D. C., S. H. Chiou, F. L. Lee, C. K. Chou, S. J. Chen, C. H. Peng, Y. H. Kuo, C. F. Chen, L. L. Ho, and W. M. Hsu. 2003. Possible involvement of nitric oxide in the progression of diabetic retinopathy. Ophthalmologica 217:342-346.[CrossRef][Medline]
29 - Van Dervort, A. L., L. Yan, P. J. Madara, J. P. Cobb, R. A. Wesley, C. C. Corriveau, M. M. Tropea, and R. L. Danner. 1994. Nitric oxide regulates endotoxin-induced TNF-alpha production by human neutrophils. J. Immunol. 152:4102-4109.[Abstract]
30 - van Steenbergen, T. J., M. F. Timmerman, F. H. Mikx, G. de Quincey, G. A. van der Weijden, U. van der Velden, and J. de Graaff. 1996. Discrepancy between culture and DNA probe analysis for the detection of periodontal bacteria. J. Clin. Periodontol. 23:955-959.[CrossRef][Medline]
31 - van't Hof, R. J., and S. H. Ralston. 2001. Nitric oxide and bone. Immunology 103:255-261.[CrossRef][Medline]
32 - Wong, J. M., and T. R. Billiar. 1995. Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Adv. Pharmacol. 34:155-170.[Medline]
33 - Zamora, R., Y. Vodovotz, and T. R. Billiar. 2000. Inducible nitric oxide synthase and inflammatory diseases. Mol. Med. 6:347-373.[Medline]
Infection and Immunity, December 2006, p. 7010-7013, Vol. 74, No. 12
0019-9567/06/$08.00+0 doi:10.1128/IAI.00071-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Sundararaj, K. P., Samuvel, D. J., Li, Y., Sanders, J. J., Lopes-Virella, M. F., Huang, Y.
(2009). Interleukin-6 Released from Fibroblasts Is Essential for Up-regulation of Matrix Metalloproteinase-1 Expression by U937 Macrophages in Coculture: CROSS-TALKING BETWEEN FIBROBLASTS AND U937 MACROPHAGES EXPOSED TO HIGH GLUCOSE. J. Biol. Chem.
284: 13714-13724
[Abstract]
[Full Text]
-
Ghosh, A., Park, J. Y., Fenno, C., Kapila, Y. L.
(2008). Porphyromonas gingivalis, Gamma Interferon, and a Proapoptotic Fibronectin Matrix Form a Synergistic Trio That Induces c-Jun N-Terminal Kinase 1-Mediated Nitric Oxide Generation and Cell Death. Infect. Immun.
76: 5514-5523
[Abstract]
[Full Text]